Abstract
Phase1 clinical trial of high doses of Seleno-L-methionine (SLM), in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients
Journal of clinical oncology, Vol.36(6_suppl), pp.630-630
02/20/2018
DOI: 10.1200/JCO.2018.36.6_suppl.630
Abstract
630
Background: The overexpression of hypoxia induced factor (HIF) 1a/2a in ccRCC leads to up-regulation of vascular endothelial growth factor (VEGF) that results in increased angiogenesis, tumor metastasis, and treatment resistance. Using several preclinical xenograft models, it has been demonstrated that therapeutic doses and schedules of the selenium-containing molecules, seleno-L-methionine (SLM) and methylselenocysteine (MSC) caused enhanced degradation of HIF1α/2α, down-regulation of oncogenic miRNA-210 and 155, up-regulation tumor suppressor miRNA-664 and LET-7b, and stabilization of tumor vasculature, yielding higher tumor drug uptake and protection from toxic side effects when combined with chemotherapeutic and VEGF-targeted agents. Methods: This is a phase I (3+3 design) dose finding trial of SLM (2500, 3000 or 4000 µg) given orally twice daily for 14 days, followed by once a day in combination with the standard dose of axitinib to patients with metastatic RCC. Primary endpoint is safety, secondary endpoint is efficacy including overall response rate (ORR), progression free survival (PFS) and overall survival (OS). Results: To date, 9 patients with metastatic RCC; who failed one or more prior lines of treatment; are enrolled. The first 3 patients were treated at 4000 µg, the second and third 3 patients were treated at 2500 and 3000 µg respectively. No dose limiting toxicity (DLT) is encountered. Six patients are evaluable to date. Of the 4000 µg cohort, 2 patients achieved complete remission (CR) at 18 and 20 months, 1 patient with partial response (PR) at 19 month. Of the 2500 µg cohort, one patient achieved PR at 9 months, 1 patient had stable disease for 9 months before progression, and 1 patient had disease progression at 4 months. The 3000 µg cohort is too early to evaluate for efficacy. Of interest the 4000μg SLM dose yielded a plasma selenium concentration of 40-50μM which is comparable with SLM dose determined synergistic with anti-cancer drugs in preclinical models. Conclusions: High dose SLM is safe in combination with axitinib, with promising efficacy, further data to be presented at the meeting. Clinical trial information: NCT02535533.
Details
- Title: Subtitle
- Phase1 clinical trial of high doses of Seleno-L-methionine (SLM), in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients
- Creators
- Yousef Zakharia - University of IowaRohan Garje - University of IowaJames A. Brown - University of IowaKenneth Gerard Nepple - University of IowaLaila Dahmoush - University of IowaKatherine Gibson-Corley - University of IowaDouglas Spitz - University of IowaMohammed M. Milhem - University of IowaYoucef M. Rustum - Roswell Park Cancer Institute
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(6_suppl), pp.630-630
- DOI
- 10.1200/JCO.2018.36.6_suppl.630
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 02/20/2018
- Academic Unit
- Pathology; Roy J. Carver Department of Biomedical Engineering; Fraternal Order of Eagles Diabetes Research Center; Hematology, Oncology, and Blood & Marrow Transplantation; The University of Iowa Institute for Vision Research; Internal Medicine; Urology; Radiation Oncology
- Record Identifier
- 9984321547002771
Metrics
9 Record Views